middle.news
Firebrick Pharma Expands Patent Portfolio and Reports 43% Sales Growth
9:32am on Monday 27th of July, 2026 AEST
•
Healthcare
Read Story
Firebrick Pharma Expands Patent Portfolio and Reports 43% Sales Growth
9:32am on Monday 27th of July, 2026 AEST
Key Points
Two new patents granted in Canada and New Zealand
FY26 sales increased 43% after adjusting for one-off receipts
Quarterly cash burn steady at $768k with $1.32m cash on hand
Nasodine approved in Indonesia; Philippines approval pending
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Firebrick Pharma (ASX:FRE)
OPEN ARTICLE